Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the ...
Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...
Ex-Intel head says TSMC’s new investment will not resurrect US chip sector Read the Market Summary Here:- Highlighted with 142 tables and 105 figures, this 228-page report ?Global Pharmaceutical ...
MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Data Expected in April 2025 from Part 2 of Phase 1 Trial of DA-1726 ...
Potential US tariffs on pharmaceuticals could set off a ripple effect that extends far beyond the immediate price hikes, as ...
Company announcement - No. 7 / 2025 Resolutions from Zealand Pharma's Annual General Meeting 2025 Copenhagen, Denmark, March 27, 2025 - Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL) (CVR-no. 20045078) ...
Zacks Investment Research on MSN6d
VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss DrugViking Therapeutics VKTX announced that it has completed enrolling study participants in the phase II VENTURE-Oral Dosing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback